朗生醫藥(00503.HK)2020年淨利同比增長380.7%至8820.5萬美元
格隆匯 3 月 30日丨朗生醫藥(00503.HK)公吿,截至2020年12月31日止年度業績,收入5438.6萬美元,同比增長0.2%;公司擁有人應占溢利8820.5萬美元,同比增長380.7%;基本每股盈利22.21美仙。無派息。
面對多變以及充滿挑戰的營運環境,集團延續以"自有產品優先、利潤優先、現金流優先"的發展導向。受惠於此政策導引,2020年度醫藥部門的整體銷售維持平穩且略有增長,自有專科藥產品帕夫林及新適確得繼續維持增長,醫藥業務繼續下沉銷售管道,加大產品組合,增強線上推廣及完善銷售平台的建設。健康及美容業務目前仍在培育階段,集團會繼續利用內部資源發展健康及美容業務。集團亦計劃在未來數年內陸續復產集團儲備的中藥產品。
毛利較高的自有專科藥產品(帕夫林及新適確得)的銷售佔比較去年上升及採購招標等成精細管控的進一步推進令整體毛利率上升。
同時,由於繼續貫徹控制費用的政策及受新冠肺炎疫情影響,集團減少線下銷售及分銷活動而使銷售及分銷開支較去年有所下降。行政開支減少是因去年有若干存貨進行撥備及撇賬,今年度的撥備及撇賬較去年大幅減少;另外由於人民幣兑美金升值,集團因持有相關人民幣資金而錄得匯兑收益增幅較多。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.